Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
Holding ALEC?
Track your performance easily
Earnings Data
Report Date
Apr 01, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.62Last Year’s EPS
-$0.38Same Quarter Last Year
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -64.50%
|Next Earnings Date:Apr 01, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial health and advancements in clinical programs, particularly with AL002 and latozinemab. However, challenges such as MRI abnormalities in trials and uncertain regulatory pathways present potential hurdles.Company Guidance
During Alector's Q2 2024 earnings call, the company provided significant guidance on its ongoing and upcoming programs, emphasizing its robust financial positioning with a cash reserve of $503.3 million, ensuring funding through 2026. The call highlighted the upcoming data readout for the AL002 Phase II trial, INVOKE-2, expected in Q4 2024, exploring its potential in early Alzheimer's disease with a focus on TREM2 signaling. Alector discussed the trial's enrollment of 381 participants, with 67% having mild cognitive impairment and 33% mild dementia, and noted a mean amyloid PET centiloid level of 100.1. The company anticipates collaboration revenue between $60 million and $70 million for 2024 and has earmarked $210 million to $220 million for research and development expenses. Additionally, Alector outlined its strategic advancements with the Alector Brain Carrier (ABC) platform for enhancing drug delivery across the blood-brain barrier and detailed plans for the latozinemab program, which received FDA breakthrough therapy designation, with a pivotal Phase III data readout expected in late 2025 or early 2026.Strong Cash Position
ALEC ended Q2 2024 with a cash position of $503.3 million, extending the cash runway through 2026, covering key milestones like the AL002 INVOKE-2 Phase II data readout and the pivotal INFRONT-3 Phase III data readout.
Advancements in AL002 and Latozinemab Programs
AL002, a TREM2 agonist, is in a Phase II trial expected to read out in Q4 2024. Latozinemab received breakthrough therapy designation, potentially expediting interactions with the FDA.
Introduction of Alector Brain Carrier (ABC) Technology
The ABC platform aims to enhance drug delivery across the blood-brain barrier, improving the efficacy and reducing costs for neurodegenerative disease treatments.
---
ALEC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALEC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $5.24 | $5.64 | +7.63% |
| Aug 07, 2024 | $4.91 | $5.10 | +3.87% |
| May 08, 2024 | $5.19 | $5.20 | +0.19% |
| Feb 27, 2024 | $7.01 | $6.99 | -0.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Alector Inc (ALEC) report earnings?
Alector Inc (ALEC) is schdueled to report earning on Apr 01, 2025, TBA Not Confirmed.
What is Alector Inc (ALEC) earnings time?
Alector Inc (ALEC) earnings time is at Apr 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALEC EPS forecast?
ALEC EPS forecast for the fiscal quarter 2024 (Q4) is -$0.62.
---